S. Amin-hanjani et al., Mevastatin, an HMG-CoA reductase inhibitor, reduces stroke damage and upregulates endothelial nitric oxide synthase in mice, STROKE, 32(4), 2001, pp. 980-985
Background and Purpose-The 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA)
reductase inhibitors (statins) lower serum cholesterol and decrease the inc
idence of stroke and cardiovascular disease. There is growing evidence that
statins exert some of their beneficial effects independent of cholesterol
lowering. Indeed, we have previously demonstrated that chronic simvastatin
administration upregulates endothelial nitric oxide synthase (eNOS), result
ing in more functional protein, augmentation of cerebral blood flow, and ne
uroprotection in a murine model of cerebral ischemia. In this report we exa
mined whether another member of the statin family shared these effects and
whether eNOS upregulation is sustained with longer treatment.
Methods-Mevastatin (2 mg/kg or 20 mg/kg per day) was administered to 18- to
22-g male mice for 7, 14, or 28 days before 2-hour middle cerebral artery
occlusion with the use of the filament model (n = 9 to 12). Neurological de
ficits and cerebral infarct volumes were assessed at 24 hours. Arterial blo
od pressure and gases, relative cerebral blood flow, and blood cholesterol
levels were monitored in a subset of animals (n=5). Absolute cerebral blood
flow was measured by the [C-14]iodoamphetamine indicator fractionation tec
hnique (n=6), eNOS mRNA and protein levels were determined.
Results-Mevastatin increased levels of eNOS mRNA and protein, reduced infar
ct size, and improved neurological deficits in a dose- and time-dependent m
anner. Greatest protection was seen with 13- and 25-day high-dose treatment
(26% and 37% infarct reduction, respectively). Cholesterol levels were red
uced only after 28 days of treatment and did not correlate with infarct red
uction. Baseline absolute cerebral blood flow was 30% higher after 14-day h
igh-dose treatment.
Conclusions-Chronic prophylactic treatment with mevastatin upregulated eNOS
and augmented cerebral blood flow. These changes occurred in the absence o
f changes in serum cholesterol levels, were sustained for up to 1 month of
treatment, and resulted in neuroprotection after middle cerebral artery occ
lusion.